
    
      This is an extension study for all participants who completed study 211LE201 (NCT01499355)
      through Week 52 and did not discontinue BIIB023 or placebo. Eligible participants from Study
      211LE201 will be followed for up to 108 weeks.

      Participants who received BIIB023 low dose or high dose in 211LE201 will continue to receive
      the same dosing in this study (211LE202; NCT01930890) in addition to background therapy.
      Participants who received placebo in 211LE201 are randomized to receive either BIIB023 low
      dose or high dose in addition to background therapy.
    
  